Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer

BACKGROUND: Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop novel t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haiyong, Wu, Jing, Yuan, Jinqiu, Li, Huafu, Zhang, Yawei, Wu, Wang, Chen, Wei, Wang, Chunming, Meng, Sijun, Chen, Songyao, Huo, Mingyu, He, Yulong, Zhang, Changhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375208/
https://www.ncbi.nlm.nih.gov/pubmed/34412665
http://dx.doi.org/10.1186/s13046-021-02052-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375208/
https://www.ncbi.nlm.nih.gov/pubmed/34412665
http://dx.doi.org/10.1186/s13046-021-02052-z

Ejemplares similares